6月15日，科伦博泰生物盘中上涨3.03%，报420.2港元，成交额6105.08万港元。
消息面上，公司于6月12日公告披露，已收到宜联生物医药根据和解协议支付的款项合计人民币7.03亿元，其中包含YL201对外授权应分享给公司的收入6.025亿元。根据双方和解协议，宜联生物需就其管线内包括YL201、YL212等6款ADC药物向科伦博泰分享对外授权收入及净利润，7.03亿元为"首期兑现"，后续管线授权里程碑达成及产品商业化仍有持续分成空间。此外，多家券商近期维持"买入"评级，野村上调目标价至544.42港元，核心产品芦康沙妥珠单抗III期数据积极，合作伙伴Windward Bio超长效抗TSLP抗体II期临床亦完成首批给药，多重利好共振支撑股价延续强势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.